My HPRA: Register

The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Zessly



Sandoz GmbHEU/1/18/1280/001-005

Main Information

Trade NameZessly
Active SubstancesInfliximab
Dosage FormPowder for concentrate for solution for infusion
Licence HolderSandoz GmbH
Licence NumberEU/1/18/1280/001-005

Group Information

ATC CodeL04AB Tumor necrosis factor alpha (TNF-) inhibitors
L04AB02 infliximab

Status

License statusAuthorised
Licence Issued18/05/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back
Follow medicine

Print